Smoking cessation after an acute coronary syndrome: immediate quitters are successful quitters by unknown
Original article
Published online: 8 October 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com
Smoking cessation after an acute coronary syndrome: immediate 
quitters are successful quitters
M. Snaterse · W.J.M. Scholte op Reimer · J. Dobber ·  
M. Minneboo · G. ter  Riet · H.T. Jorstad ·  
S.M. Boekholdt · R.J.G. Peters
Neth Heart J (2015) 23:600–607
DOI 10.1007/s12471-015-0755-9
cholesterol level at 1 year (78 vs. 63 %, p < 0.01) were as-
sociated with successful quitting.
Conclusion The majority of successful quitters at 1 year 
stopped immediately after their ACS. Patients in this group 
showed that it was within their own ability to quit, and they 
did not relapse through 1 year of follow-up. Our study indi-
cates that in a large group of patients who quit immediately 
after a life-threatening event, no relapse prevention program 
is needed.
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Introduction
Coronary heart disease (CHD) patients are at high risk of 
recurrent coronary events and mortality. Risk reduction 
strategies are therefore offered to patients with established 
CHD or other atherosclerotic cardiovascular disease (CVD). 
Smoking is known to be a major health risk factor [1, 2]. 
Smoking cessation after CHD is diagnosed is potentially the 
most effective preventive measure. It is associated with a 
33 %-50 % reduction in risk of recurrent myocardial infarc-
tions or cardiovascular death [3–5] and a life expectancy 
gain of 3 years after coronary artery bypass surgery [6]. 
Nevertheless, although smoking cessation is potentially the 
most effective CVD prevention strategy, quitting smoking 
is difficult and secondary prevention is suboptimal. Stud-
ies from Europe and the USA have shown that half of the 
patients continue to smoke despite a life-threatening event 
[7, 8]. Although the majority received personal advice to 
stop or were offered counselling, many were not able to quit 
[7, 9]. In general, surveys revealed a disappointing situation 
with regard to secondary prevention actions. A substantial 
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Background Cardiovascular disease (CVD) prevention 
guidelines stress the importance of smoking cessation and 
recommend intensive follow-up. To guide the development 
of such cessation support strategies, we analysed the char-
acteristics that are associated with successful smoking ces-
sation after an acute coronary syndrome (ACS).
Methods We used data from the Randomised Evaluation of 
Secondary Prevention for ACS patients coordinated by Out-
patient Nurse SpEcialists (RESPONSE) trial (n = 754). This 
was designed to quantify the impact of a nurse-coordinated 
prevention program, focusing on healthy lifestyles, tradi-
tional CVD risk factors and medication adherence. For the 
current analysis we included all smokers (324/754, 43 %). 
Successful quitters were defined as those who reported ab-
stinence at 1 year of follow-up.
Results The majority of successful quitters quit immedi-
ately after the ACS event and remained abstinent through 
1 year of follow-up, without extra support (128/156, 82 %). 
Higher education level (33 vs. 15 %, p < 0.01), no history of 
CVD (87 vs. 74 %, p < 0.01) and being on target for LDL-
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potential to reduce the risk of recurrent cardiovascular dis-
ease or death still remains.
Successful strategies for smoking cessation include 
pharmacological therapy (nicotine replacement therapy, 
bupropion and varenicline) and behavioural counselling for 
smokers willing to quit [10–12] Successful behavioural sup-
port in smoking cessation has been reported for group ther-
apy, individual counselling [11] and telephone counselling 
[13] and to a lesser extent for individually tailored self-help 
materials [11]. In addition, guidelines on CVD prevention 
recommend frequent follow-up visits for all smokers who 
have quit to increase long-term success [14]. However, as 
shown in a recent review [15], the effectiveness of behav-
ioural relapse prevention methods for any initially success-
ful subgroup of former smokers has not been demonstrated.
Nurse-coordinated prevention programs also aim to 
increase the proportion of patients achieving CVD preven-
tion targets, but these initiatives have not resulted in higher 
smoking cessation rates [16–19]. With the RESPONSE 
trial we evaluated whether a nurse-coordinated prevention 
program leads to better achievement of guideline-recom-
mended CVD prevention targets [20]. We found this pro-
gram improved blood pressure and lipid management, but 
did not have a significant impact on lifestyle factors, includ-
ing smoking cessation [20].
It is currently unknown which patients benefit from inten-
sive smoking cessation counselling after hospital admission 
for acute coronary syndrome (ACS). Better understanding 
of the characteristics of patients who are likely to quit suc-
cessfully after ACS may provide useful information to guide 
development of more effective smoking cessation interven-
tions. We therefore addressed the following research ques-
tion: what are the characteristics of successful quitters after 
a recent ACS?
Methods
Design and study population
The RESPONSE trial (n = 754) was a multicentre, ran-
domised controlled trial conducted in 11 centres in the 
Netherlands with 1 year of follow-up. Patients aged 18–80 
years were eligible if they had been diagnosed and hospi-
talised with ACS within 8 weeks prior to enrolment in the 
trial. Patients were excluded if they (1) were unable to visit 
the nurse-coordinated prevention program, (2) were not 
available for follow-up, (3) had a limited life expectancy 
(≤ 2 years), and (4) were diagnosed with a New York Heart 
Association class III or class IV heart failure. Patients were 
randomised to either the nurse-coordinated prevention pro-
gram or usual care alone. Detailed information about the 
study methods has been reported elsewhere [20, 21]. For 
the current analyses, we selected 324 patients who smoked 
before the index ACS event (43 %) and reported a smoking 
and quitting status at 1 year of follow-up.
We defined successful quitters as patients who reported 
abstinence accompanied by a quit date at 1 year of follow-
up. We defined relapsers as those patients who had attempted 
to quit smoking but reported that they began smoking again 
within 1 year, and were therefore classified as ‘smoker’ 
in the main analysis at 1 year of follow-up. Patients who 
reported that they continued smoking in the year of follow-
up were also classified as smokers.
Data collection and follow-up
Baseline measurements were performed within 8 weeks 
after ACS. Patients were enrolled at an average of 4 weeks 
(SD 2.7). Patients in the intervention group visited the out-
patient clinic four times during the first 6 months after inclu-
sion, in addition to visits to their treating cardiologist (usual 
care). During each nurse visit cardiovascular risk factors 
were evaluated. Data on clinical and demographic charac-
teristics, CHD risk factors and smoking quit dates were col-
lected at baseline and follow-up. Smoking behaviour was 
measured by means of interview questions. Health-related 
quality of life was assessed with the MacNew questionnaire 
[22, 23]. Scores on each quality of life domain were cal-
culated as the average of the responses in that domain. We 
used the Systematic Coronary Risk Evaluation (SCORE) 
as an integrated measure to estimate the overall impact of 
smoking cessation on cardiovascular risk.
Statistical analysis
The results of our statistical analysis are presented as abso-
lute numbers and percentages. Differences between success-
ful quitters and smokers were analysed by using unpaired 
t-tests for continuous variables and chi-square statistics for 
categorical variables. We used SPSS (version 20.0) for all 
data analysis.
Results
Of 324 smokers admitted to hospital with ACS, 186 (57 %) 
reported a cessation attempt in the year after the event. Of 
those, 156 (86 %) were successful quitters in up to 1 year of 
follow-up. The majority of this group quit immediately after 
the event (128/156, 82 %; Fig. 1) and received no smok-
ing cessation counselling after discharge. Patients making 
a later cessation attempt were less successful in quitting 
smoking (28/44, 64 %).
As shown in Table 1, successful quitting up to 1 year after 
ACS was associated with a higher education level (33 vs. 
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This group was encouraged to quit smoking and was given 
information about a healthy lifestyle. However, participa-
tion in the nurse-coordinated prevention program group did 
not significantly increase smoking cessation rates in patients 
making a late attempt (p = 0.8).
Discussion
Our study demonstrates that immediate cessation after hos-
pitalisation for ACS is the most important characteristic 
of successful quitters. A higher level of education, no his-
tory of CVD, LDL-cholesterol level on target and adequate 
physical activity at 1 year characterised successful quitters 
at 1 year after ACS as well. At 1 year, however, successful 
quitters more often had a BMI > 25 kg/m2 compared with 
smokers.
The REPONSE trial showed that a nurse-coordinated 
prevention program improved systolic blood pressure and 
blood levels of LDL-cholesterol. However, this program 
was less successful in achieving smoking cessation [20]. 
In the current paper we explored characteristics that may 
increase successful smoking cessation, for smoking is a 
major risk factor of mortality and recurrent events in CHD 
patients.
Our study confirms that quitting smoking is extremely 
difficult for many patients, even after being hospitalised for 
a life-threatening event, especially for those with a lower 
education level. Only half of the patients succeeded in quit-
ting smoking after ACS, which is consistent with success 
rates in previous studies [7, 9].
On the positive side, however, our study also shows that 
almost half of all smokers succeeded in quitting up to 1 year 
after ACS. Moreover, of those who quit immediately after 
the acute event, the majority are successful through 1 year. 
Our study confirms earlier findings indicating that a clinical 
event acts as an important motivator and may induce behav-
ioural change [24], particularly if this event is perceived as 
life-threatening as is the case with patients’ first ACS [9, 
25]. In accordance with European Society of Cardiology 
(ESC) guidelines, clinicians may make greater use of this 
opportunity by addressing the issue before discharge [14]. 
These guidelines also recommend that support for cessa-
tion of smoking is initiated for all smokers during hospital 
admission and is continued for a prolonged period after dis-
charge [10, 14]. Our study shows, however, that the major-
ity of successful quitters stop immediately after discharge, 
triggered by the ACS event, and that it is within their own 
ability to quit and remain abstinent.
This continued change of behaviour may be explained by 
the theory of self-perception, which describes how people 
use their own behaviour to learn what they believe [24]. 
In our study, during admission almost half of the smokers 
15 %, p < 0.01), no history of CVD (87 vs. 74 %, p < 0.01), 
being on target for LDL-cholesterol level at 1 year (78 vs. 
63 %, p < 0.01) and adequate physical activity at 1 year (65 
vs. 52 %, p = 0.01).
At 12 months, the estimated SCORE cardiovascular 
10-year mortality risk was 2.9 % (SD 0.03) for successful 
quitters and 5.7 % (SD 0.07) for smokers (p < 0.01). Suc-
cessful quitters and smokers were comparable in other life-
style risk factors than smoking at baseline, while after 1 year 
successful quitters more frequently had a body mass index 
(BMI) > 25 kg/m2 compared with smokers (81 vs. 67 %, 
p < 0.01) Mean BMI at 1 year was 29.0 kg/m2 (SD 4.93) in 
successful quitters and 27.5 kg/m2 (SD 5.04) in smokers. 
Smoking cessation after ACS was associated with an aver-
age weight gain of 3.36 kg (SD 5.48) at 1 year. In our study 
we observed a maximal weight gain in successful quitters 
of 21 kg, whereas 9 % of successful quitters gained > 10 kg 
after smoking cessation.
Within the group of smokers, 63 % reduced smoking cig-
arettes at 1 year of follow-up compared with baseline level. 
These patients had a higher level of education and smoked 
a higher number of cigarettes per day compared with smok-
ers not reducing cigarette smoking. We observed a median 
reduction of 5 (IQR 0–15) cigarettes for smokers at 1 year 
of follow-up. In smokers who reduced cigarette smoking, 
we found that after 1 year they smoked a median of 13 ciga-
rettes (IQR 6–20) less than at baseline.
In total, 30 relapsers were presented (Table 1). The 
majority (90 %) of these were younger than 60 years of 
age, relatively more were female (33 %) than both success-
ful quitters and smokers and diagnosed with ST-segment-
elevation myocardial infarction (60 %). We found that a 
group of 14 relapsers before baseline measurements were 
predominantly male coronary artery bypass graft (CABG) 
patients (86 %).
Of 44 patients making later cessation attempts, 73 % 
were in the nurse-coordinated prevention program group. 
Fig. 1 Flowchart of 324 smokers after an acute coronary syndrome 
(ACS) from hospital admission up to 1-year follow-up
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gered by an acute life-threatening event or other triggers 
and immediate or late quitters. In patients hospitalised for 
acute events who immediately quit after discharge, and do 
not relapse up to their first outpatient clinic visit, relapse 
prevention by counselling or pharmacological therapy may 
not be necessary. In our study, none of the immediate quit-
ters who remained abstinent up to their first outpatient visit 
reported a relapse up to 1 year after ACS, and evidence for 
the effectiveness of relapse prevention for patients who 
immediately quit smoking after an acute hospitalisation is 
lacking [15].
Our results are, however, less clear about the effective-
ness of smoking cessation interventions at hospital dis-
charge, as we observed a number of relapsers between 
hospital discharge and the first visit to the outpatient clinic. 
This occurred particularly in CABG patients, who may feel 
showed that they were willing to change and felt able to 
change. The feeling of being able to change is strengthened 
when these patients indeed quit smoking after discharge. 
These patients soon perceive themselves as ‘successful 
quitters’ [24], which subsequently strengthens them in their 
resolve to remain abstinent. Moreover, for these patients- 
who are in a ‘ready for action’ stage, according to the stages 
of change theory of Prochaska and Diclemente [26] - coun-
selling seems unnecessary and may be even counterproduc-
tive [24, 27]. The results of our study therefore suggest that 
the WHO smoking cessation algorithm, which is included 
in the ESC guideline and recommends intensive follow-up 
for all smokers, may not be appropriate for smokers who 
quit immediately after ACS. In the decision-making process 
about smoking cessation interventions, a distinction could 
be made between types of smokers, such as quitters trig-
Table 1 Characteristics of successful quitters versus smokers in ACS patients (n = 324) Immediate: immediately after hospital discharge; late: 
during one year of follow-up.
Successful quittersa n = 156 Smokers n = 168 P-valueb Relapsersc n = 30
Age
 < 50 years 53 (34 %) 61 (36 %) 0.89 14 (47 %)
 50–59 years 67 (43 %) 71 (42 %) 13 (43 %)
 ≥ 60 years 36 (23 %) 36 (21 %) 3 (10 %)
Male, n (%) 127 (81 %) 125 (74 %) 0.13 20 (67 %)
Highest level of education, n (%)
 Fewer than 8 years 41 (28 %) 63 (38 %) 0.02 13 (43 %)
 College or university 49 (33 %) 25 (15 %) < 0.001 5 (17 %)
 No history of CVD, n (%) 136 (87 %) 124 (74 %) < 0.01 19 (63 %)
Index event, n (%)
 STEMI 89 (57 %) 89 (53 %) 0.89 18 (60 %)
 NSTEMI 50 (32 %) 51 (30 %) 7 (23 %)
 Unstable angina pectoris 17 (11 %) 26 (16 %) 4 (13 %)
Nurse Coordinated Prevention Programme 89 (57 %) 83 (49 %) 0.17 16 (53 %)
No. cigarettes/day
 ≤ 10 62 (40 %) 59 (35 %) 0.36 10 (33 %)
 > 10 93 (60 %) 109 (65 %) 20 (67 %)
Quality of life at baselined (mean, SD) 5.13 (1.06) 5.02 (1.14) 0.47 5.0 (0.9)
Quality of life at 1-year follow-up 5.66 (1.01) 5.46 (0.99) 0.66 5.6 (0.7)
Risk factors at baseline
Systolic blood pressure > 140 mmHg 36 (24 %) 33 (20 %) 0.12 4 (13 %)
LDL-cholesterol > 2.5 mmol/L 46 (31 %) 66 (39 %) 0.15 13 (43 %)
Body mass index > 25 kg/m2 116 (74 %) 115 (68 %) 0.12 22 (73 %)
Inadequate physical activitye 89 (57 %) 98 (58 %) 0.81 16 (53 %)
Risk factors at 1-year follow-up
Systolic blood pressure > 140 mmHg 41 (28 %) 43 (26 %) 0.79 9 (30 %)
LDL-cholesterol > 2.5 mmol/L 32 (22 %) 62 (37 %) < 0.01 16 (57 %)
Body mass index > 25 kg/m2 127 (81 %) 112 (67 %) < 0.01 23 (78 %)
Inadequate physical activity 54 (35 %) 81 (48 %) 0.01 15 (50 %)
Systematic Coronary Risk Evaluation (SCORE) 2.9 % 5.7 % < 0.01 4.2 %
aDefined as non-smoking at outcome assessment date;
bBetween successful quitters and smokers;
cnote that these 30 relapsers are a subgroup of the 168 smokers;
dassessed with the MacNew questionnaire;
e< 30 min/5 times a week.
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to support the use of relapse prevention in ACS patients 
who stop smoking immediately after the event, and our 
study indicates that there is no need for this during follow-
up visits in a large group of patients. The momentum for 
smoking cessation is particularly strong immediately after 
ACS and our study reinforces the importance of clinicians’ 
explicit advice to stop smoking during hospitalisation of 
ACS patients. New strategies are needed in patients with 
a late attempt. Smoking cessation strategies in secondary 
prevention could differentiate between acute and non-acute 
patients, since an acute event acts as an important motiva-
tor for behavioural change. Furthermore smoking cessation 
support should differentiate between immediate and late 
attempts, since relapse prevention seems unnecessary for 
immediate quitters. However, patients with a late attempt 
may benefit from more intensive therapy. Future research 
is needed to assess the cost-effectiveness of differentiating 
between acute or non-acute admissions and immediate or 
late quit attempts.
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